MID-VOLUME · SEX-BALANCED
eszopiclone Side Effects
eszopiclone (also sold as Lunesta) sits MID-VOLUME #210 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 66% of sex-coded reports are female (15,412 F / 8,046 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 24,883
- FAERS reports
FDA Adverse Event Reporting System extract for eszopiclone. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
eszopiclone reporting skew - 66% of sex-coded reports are female (15,412 F / 8,046 M). Volume band MID-VOLUME #210 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for eszopiclone (Lunesta) (24,883 reports). Signature SEX-BALANCED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2005–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
INSOMNIA leads 3,888 of 24,883 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (7,295 reports)
Reporting taper since 2005 peak
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,650 reports, 6.6%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 520 |
| DEATH | 348 |
| TOXICITY TO VARIOUS AGENTS | 176 |
| CARDIO-RESPIRATORY ARREST | 111 |
| CARDIAC ARREST | 110 |
| RESPIRATORY ARREST | 74 |
| PNEUMONIA | 67 |
| DYSPNOEA | 64 |
| PAIN | 60 |
| VOMITING | 59 |
| RESPIRATORY FAILURE | 56 |
| OVERDOSE | 55 |
| PYREXIA | 52 |
| NAUSEA | 51 |
| FALL | 49 |
| RENAL FAILURE | 46 |
| INTERSTITIAL LUNG DISEASE | 44 |
| DECREASED APPETITE | 41 |
| DIARRHOEA | 41 |
| INSOMNIA | 41 |
Reactions in Hospitalization Reports
Hospitalization mid-share (4,535, 18.2%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| NAUSEA | 358 |
| FALL | 339 |
| PNEUMONIA | 298 |
| PAIN | 292 |
| DYSPNOEA | 284 |
| FATIGUE | 254 |
| ANXIETY | 247 |
| VOMITING | 235 |
| INSOMNIA | 234 |
| DIARRHOEA | 219 |
| PYREXIA | 218 |
| DEPRESSION | 216 |
| HEADACHE | 197 |
| DEHYDRATION | 182 |
| DIZZINESS | 181 |
| ASTHENIA | 176 |
| OVERDOSE | 164 |
| CHEST PAIN | 159 |
| SUICIDE ATTEMPT | 157 |
| DECREASED APPETITE | 154 |
How to read eszopiclone FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 24,883 voluntary reports linked to eszopiclone (Lunesta), 2005-2025. Death is listed on 1,650 (6.6%). Hospitalization appears on 4,535 (18.2%). Top co-reported indication: Insomnia.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 66% of sex-coded reports are female (15,412 F / 8,046 M).
Read with eszopiclone
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 24,979 FAERS cases (Δ 96 heavier vs eszopiclone); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 25,027 FAERS cases (Δ 144 heavier vs eszopiclone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 24,667 FAERS cases (Δ 216 lighter vs eszopiclone); DEATH-MARKED · HOSP-LIGHT · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 25,229 FAERS cases (Δ 346 heavier vs eszopiclone); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 55.5 pp vs eszopiclone's DEATH-HEAVY): CASELOAD · HOSP-MID.
eszopiclone stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.